BACKGROUND: Topoisomerase II is essential for the maintenance of DNA integrity and the survival of proliferating cells. Topoisomerase II poisons, including etoposide and doxorubicin, inhibit enzyme-mediated DNA ligation causing the accumulation of double-stranded breaks and have been front-line drugs for the treatment of leukemia for many years. Voreloxin is a first-in-class anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. The efficacy and mechanisms of action of voreloxin in acute myeloid leukaemia were addressed in this study. DESIGN AND METHODS: Primary acute myeloid leukemia blasts (n = 88) and myeloid cell lines were used in vitro to study voreloxin through viability assays to assess cell killing and synergy with other drugs. Apoptosis and cell cycling were assessed by flow cytometry. DNA relaxation assays were utilized to determine that voreloxin was active on topoisomerase II. RESULTS: The mean lethal dose 50% (LD(50)) (± standard deviation) of voreloxin for primary acute myeloid leukemia blasts was 2.30 μM (± 1.87). Synergy experiments between voreloxin and cytarabine identified synergism in 22 of 25 primary acute myeloid leukemia samples tested, with a mean combination index of 0.79. Apoptosis was shown to increase in a dose-dependent manner. Furthermore, voreloxin was active in the p53-null K562 cell line suggesting that the action of voreloxin is not affected by p53 status. The action of voreloxin on topoisomerase II was confirmed using a DNA relaxation assay. CONCLUSIONS: Voreloxin may provide an interesting addition to the cache of drugs available for the treatment of acute myeloid leukemia, a disease with a poor long-term survival. In addition to its potent action as a single agent in dividing cells, the synergy we demonstrated between voreloxin and cytarabine recommends further investigation of this topoisomerase II inhibitor.
BACKGROUND: Topoisomerase II is essential for the maintenance of DNA integrity and the survival of proliferating cells. Topoisomerase II poisons, including etoposide and doxorubicin, inhibit enzyme-mediated DNA ligation causing the accumulation of double-stranded breaks and have been front-line drugs for the treatment of leukemia for many years. Voreloxin is a first-in-class anti-cancerquinolone derivative that intercalates DNA and inhibits topoisomerase II. The efficacy and mechanisms of action of voreloxin in acute myeloid leukaemia were addressed in this study. DESIGN AND METHODS: Primary acute myeloid leukemia blasts (n = 88) and myeloid cell lines were used in vitro to study voreloxin through viability assays to assess cell killing and synergy with other drugs. Apoptosis and cell cycling were assessed by flow cytometry. DNA relaxation assays were utilized to determine that voreloxin was active on topoisomerase II. RESULTS: The mean lethal dose 50% (LD(50)) (± standard deviation) of voreloxin for primary acute myeloid leukemia blasts was 2.30 μM (± 1.87). Synergy experiments between voreloxin and cytarabine identified synergism in 22 of 25 primary acute myeloid leukemia samples tested, with a mean combination index of 0.79. Apoptosis was shown to increase in a dose-dependent manner. Furthermore, voreloxin was active in the p53-null K562 cell line suggesting that the action of voreloxin is not affected by p53 status. The action of voreloxin on topoisomerase II was confirmed using a DNA relaxation assay. CONCLUSIONS:Voreloxin may provide an interesting addition to the cache of drugs available for the treatment of acute myeloid leukemia, a disease with a poor long-term survival. In addition to its potent action as a single agent in dividing cells, the synergy we demonstrated between voreloxin and cytarabine recommends further investigation of this topoisomerase II inhibitor.
Authors: J L Aguilar Ponce; Y Flores-Picazo; J Pérez-Urizar; G Castañeda-Hernández; J W Zinser-Sierra; A Dueñas-González; E Calderón-Flores; B A Segura-Pacheco; J de la Garza-Salazar Journal: Arch Med Res Date: 1999 May-Jun Impact factor: 2.235
Authors: H C A Graat; M A Witlox; F H E Schagen; G J L Kaspers; M N Helder; J Bras; G R Schaap; W R Gerritsen; P I J M Wuisman; V W van Beusechem Journal: Br J Cancer Date: 2006-05-30 Impact factor: 7.640
Authors: Farhad Ravandi; Ellen K Ritchie; Hamid Sayar; Jeffrey E Lancet; Michael D Craig; Norbert Vey; Stephen A Strickland; Gary J Schiller; Elias Jabbour; Arnaud Pigneux; Heinz-August Horst; Christian Récher; Virginia M Klimek; Jorge E Cortes; Angelo-Michele Carella; Miklos Egyed; Utz Krug; Judith A Fox; Adam R Craig; Renee Ward; Jennifer A Smith; Gary Acton; Hagop M Kantarjian; Robert K Stuart Journal: Haematologica Date: 2018-05-24 Impact factor: 9.941
Authors: Jeffrey E Lancet; Gail J Roboz; Larry D Cripe; Glenn C Michelson; Judith A Fox; Richard D Leavitt; Tianling Chen; Rachael Hawtin; Adam R Craig; Farhad Ravandi; Michael B Maris; Robert K Stuart; Judith E Karp Journal: Haematologica Date: 2014-11-07 Impact factor: 9.941
Authors: Elizabeth A Williamson; Leah Damiani; Andrei Leitao; Chelin Hu; Helen Hathaway; Tudor Oprea; Larry Sklar; Montaser Shaheen; Julie Bauman; Wei Wang; Jac A Nickoloff; Suk-Hee Lee; Robert Hromas Journal: Cancer Res Date: 2012-10-22 Impact factor: 12.701
Authors: Farhad Ravandi; Ellen K Ritchie; Hamid Sayar; Jeffrey E Lancet; Michael D Craig; Norbert Vey; Stephen A Strickland; Gary J Schiller; Elias Jabbour; Harry P Erba; Arnaud Pigneux; Heinz-August Horst; Christian Recher; Virginia M Klimek; Jorge Cortes; Gail J Roboz; Olatoyosi Odenike; Xavier Thomas; Violaine Havelange; Johan Maertens; Hans-Günter Derigs; Michael Heuser; Lloyd Damon; Bayard L Powell; Gianluca Gaidano; Angelo-Michele Carella; Andrew Wei; Donna Hogge; Adam R Craig; Judith A Fox; Renee Ward; Jennifer A Smith; Gary Acton; Cyrus Mehta; Robert K Stuart; Hagop M Kantarjian Journal: Lancet Oncol Date: 2015-07-30 Impact factor: 41.316